Systemic mastocytosis;Les mastocytoses systémiques

Presse Medicale

Volumn 34, Issue 9, 2005, Pages 681-687

  Fain, Olivier ^a,e   Stirnemann, J ^a   Eclache, V ^c   Barete, S ^b   Casassus, P ^d   Hermine, O ^d   Lorholary, O ^d  

^a UNIVERSITÉ PARIS 13   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL JEAN VERDIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHETAMINE; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHYMOTRYPSIN; CLADRIBINE; CODEINE; COLISTIN; CORTICOSTEROID; CORTICOTROPIN; CROMOGLYCATE DISODIUM; DEXTRAN; HALOTHANE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDRALAZINE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IODINATED CONTRAST MEDIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; MORPHINE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPIC ACID; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; POLYMYXIN B; PROTAMINE; PROTEIN TYROSINE KINASE INHIBITOR; QUININE; RESERPINE; SALICYLIC ACID; SCOPOLAMINE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; THIAMINE; TRYPTASE; TUBOCURARINE CHLORIDE; ZAFIRLUKAST;

ANAPHYLAXIS; BONE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; ENZYME BLOOD LEVEL; FLUSHING; GASTROINTESTINAL DISEASE; HISTOLOGY; HUMAN; IMMUNOPHENOTYPING; LABORATORY TEST; MAST CELL; MASTOCYTOSIS; PATHOGENESIS; PROGNOSIS; PUVA; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; SYNCOPE; URTICARIA;

EID: 20144364378     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84013-8     Document Type: Review

References (34)

1. Kitayama H, Tsujimura I, Maastsumura I, Oritani K, Ikeda H, Ishikawa J. Neoplastic transformation of normal hematopoietic cells by constituvely activating mutations of c-kit receptor tyrosine kinase. Blood 1996; 88: 995-1004.
2. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000; 28: 140-7.
3. Caillat-Vigneron N, Lortholary O, Guillevin L, Raphaël M, Casassus P. Staging of systemic mastocytosis: bone marrow scintigraphy, cytology and bone scan, a preliminary study. Blood 1994; 84(suppl): 2504.
4. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004; 11: 58-64.
5. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004 Jul 29 [Epub ahead of print].
6. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine 1988; 67: 345-68.
7. Golkar L, Bernhard JD. Mastocytosis. Lancet 1997; 349: 1379-85.
8. Rosenbaum RC, Frieri M, Metcalfe DD. Patterns of skeletal scintigraphy and their relationship to plasma and urinary histamine levels in systemic mastocytosis. J Nucl Med 1984; 25: 859-64.
9. Mican JM, Di Bisceglie AM, Fong TL, Travis WD, Kleiner DE, Baker B et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995; 22: 1163-70.
10. Sant GR, Theoharides TC, Letourneau R, Gelfand J. Interstitial cystitis and bladder mastocytosis in a woman with chronic urticaria. Scand J Urol Nephrol 1997; 31: 497-500.
11. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 2001; 57(Suppl 1): 47-55.
12. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematological disorders. Leuk Res 2001; 25: 553-62
13. Kanthawatana S, Carias K, Arnaout R, Hu J, Irani AM, Schwartz LB. The potential clinical utility of serum alpha-protryptase levels. J Allergy Clin Immunol 1999; 103: 1092-9.
14. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-25.
15. Akin C, Schwartz LB, Kitoh T, Obayashi H, Worobec A, Scott LM et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha cahin (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow morphology. Blood 2000; 96: 1267-73.
16. Galli SJ. Mast cells and basophils. Curr Opin Hematol 2000; 7: 32-9.
17. Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. Mayo Clin Proc 2002; 77: 1169-75
18. Horan RF, Sheffer AL, Austen KF Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990; 85: 852-5.
19. Godt O, Proksch E, Streit V, Christophers E. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997; 195: 35-9.
20. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004; 350: 735-6
21. Bouchelouche K, Nordling J, Hald T, Bouchelouche P. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol 2001; 166: 1734-7.
22. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997; 36: 393-6.
23. Brumsen C, Hamdy NA, Papapoulos SE. Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. Bone Miner Res 2002; 17: 567-9.
24. Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002; 119: 1090-7.
25. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, Valent P. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004; 28: 249-57.
26. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van't Wout JW, Verhoef G, Gerrits WB et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-6.
27. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127-31.
28. Lortholary O, Vargaftig J, Feger F, Pamerini F, Delarue R, Ferriole V et al. Efficacy and safety of cladribine in adult systemic mastocytosis. A French multicenter study of 33 patients Blood 2004; 104: 190a.
29. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741-4.
30. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535-6.
31. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 10: 3093-6.
32. Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005 15; 105: 2324-2331.
33. Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M, et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 2004; 34 Suppl 2: 41-52
34. Marrache F, Memain N, Bonte I, Barete S, Casassus P, de Gennes C et al. Traitement des mastocytoses systémiques. Rev Med Interne 2003; 24: 594-601.